Related Experiment Videos
Indomethacin suppository to treat primary nocturnal enuresis: double-blind study
1Private Clinic, Al-Mashtel, Baghdad, Iraq.
The Journal of Urology
|November 1, 1989
Insights
Indomethacin, a prostaglandin synthesis inhibitor, effectively treated primary nocturnal enuresis in children. This double-blind study showed it was more effective than placebo for bedwetting treatment.
Area of Science:
- Pediatric Nephrology
- Pharmacology
- Sleep Medicine
Background:
- Primary nocturnal enuresis (PNE) is involuntary urination during sleep in children.
- Current treatments for PNE have varying efficacy and side effect profiles.
- Understanding novel therapeutic targets for PNE is crucial.
Purpose of the Study:
- To evaluate the efficacy of indomethacin in treating primary nocturnal enuresis.
- To compare indomethacin's effectiveness against a placebo in a controlled setting.
Main Methods:
- A double-blind, crossover study design was employed.
- Participants included 19 children (12 girls, 7 boys) aged 6-15 years.
- Indomethacin (50-100 mg suppository) was administered and compared to placebo.
Main Results:
- Indomethacin demonstrated a statistically significant improvement in treating primary nocturnal enuresis compared to placebo.
- The study provides evidence for the therapeutic potential of prostaglandin synthesis inhibitors in PNE.
Conclusions:
- Indomethacin is an effective treatment option for primary nocturnal enuresis.
- Further research may explore optimal dosing and long-term effects of indomethacin for PNE.
Abstract:
The prostaglandin synthesis inhibitor indomethacin (used as a suppository) was compared to placebo in the treatment of primary nocturnal enuresis in a double-blind crossover study. There were 12 girls and 7 boys between 6 and 15 years old. Indomethacin (50 to 100 mg.) was significantly more effective than placebo in the treatment of primary enuresis.